The estimated Net Worth of John J Harrington is at least $1.75 million dollars as of 15 September 2021. John Harrington owns over 26,050 units of Athersys Inc stock worth over $75,631 and over the last 16 years he sold ATHX stock worth over $720,034. In addition, he makes $951,245 as Executive Vice President, Chief Scientific Officer et Director at Athersys Inc.
Sign up
John Harrington ATHX stock SEC Form 4 insiders trading
John has made over 29 trades of the Athersys Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 26,050 units of ATHX stock worth $38,033 on 15 September 2021.
The largest trade he's ever made was selling 36,000 units of Athersys Inc stock on 15 June 2017 worth over $52,200. On average, John trades about 8,562 units every 96 days since 2008. As of 15 September 2021 he still owns at least 742,941 units of Athersys Inc stock.
You can see the complete history of John Harrington stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Harrington biography
Dr. John J. Harrington Ph.D. serves as Executive Vice President, Chief Scientific Officer, Director of the Company. Dr. Harrington co-founded Athersys in 1995 and has served as our Chief Scientific Officer, Executive Vice President and Director since our founding. Dr. Harrington led the development of the RAGE® technology, as well as its application for gene discovery, drug discovery and commercial protein production applications. He is a listed inventor on numerous issued or pending United States patents, has authored many scientific publications and has received awards for his work, including being named one of the top international young scientists by MIT Technology Review in 2002. Dr. Harrington has overseen the therapeutic product development programs at Athersys since their inception and is also focused on the clinical development and manufacturing of MultiStem®. During his career, he held positions at Amgen and Scripps Clinic. He received his B.A. in Biochemistry and Cell Biology from the University of California at San Diego and his Ph.D. in Cancer Biology from Stanford University. Dr. Harrington’s scientific experience and deep understanding of our Company, combined with his drive for innovation and excellence, position him well to serve on the Board of Directors.
What is the salary of John Harrington?
As the Executive Vice President, Chief Scientific Officer et Director of Athersys Inc, the total compensation of John Harrington at Athersys Inc is $951,245. There are 1 executives at Athersys Inc getting paid more, with Gil Van Bokkelen having the highest compensation of $1,596,650.
How old is John Harrington?
John Harrington is 52, he's been the Executive Vice President, Chief Scientific Officer et Director of Athersys Inc since 2007. There are 11 older and 3 younger executives at Athersys Inc. The oldest executive at Athersys Inc is Lorin Randall, 76, who is the Independent Director.
Insiders trading at Athersys Inc
Over the last 17 years, insiders at Athersys Inc have traded over $3,715,462 worth of Athersys Inc stock and bought 2,242,389 units worth $3,620,264 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Michael B Sheffery et Jordan Davis. On average, Athersys Inc executives and independent directors trade stock every 43 days with the average trade being worth of $3,231. The most recent stock trade was executed by Daniel A. Camardo on 22 November 2022, trading 100,000 units of ATHX stock currently worth $55,000.
What does Athersys Inc do?
athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.
What does Athersys Inc's logo look like?
Complete history of John Harrington stock trades at Athersys Inc
Athersys Inc executives and stock owners
Athersys Inc executives and other stock owners filed with the SEC include:
-
Gil Van Bokkelen,
Chairman of the Board, Chief Executive Officer -
John Harrington,
Executive Vice President, Chief Scientific Officer, Director -
William Lehmann,
President, Chief Operating Officer -
Laura Campbell,
Senior Vice President - Finance -
Ivor Macleod CPA, M.B.A.,
Chief Financial Officer & Principal Accounting Officer -
Dr. John J. Harrington,
Co-Founder, Chief Scientific Officer, Exec. VP & Director -
William B. J. Lehmann Jr., M.B.A., J.D., MBA,
Pres, COO, Sec. & Interim CEO -
Lorin Randall,
Independent Director -
Jack Wyszomierski,
Independent Director -
Ismail Kola,
Independent Director -
Jane Wasman,
Director -
Baiju Shah,
Director -
Katherine Kalin,
Director -
Hardy Kagimoto,
Director -
Maia Hansen,
Senior Vice President - Operations, Supply Chain -
Ivor Macleod,
Chief Financial Officer -
Dr. Eric Jenkins M.D.,
Sr. Medical Director & Head of Clinical Operations -
Maia Hansen M.B.A., M.S.,
Sr. VP and Head of Operations & Supply Chain -
Rakesh Ramachandran,
Head of Information Technology & Communications and VP -
Dr. Robert Mays Ph.D.,
VP of Regenerative Medicine & Head of Neuroscience Programs -
Dr. Manal Morsy M.D., PH.D.,
Sr. VP & Head of Global Regulatory Affairs -
Alison O'Sullivan M.B.A.,
Sr. Director of HR -
Karen Hunady M.S.,
Director of Corp. Communications & Investor Relations -
Jordan Davis,
Director -
Lee Babiss,
Director -
Neema Mayhugh,
Director -
Joseph Patrick Nolan,
Director -
K.K. Healios,
-
Tadahisa Kagimoto,
Director -
Robert J Deans,
Sr. Vice President -
Kenneth Traub,
Director -
Advisors Llc Orbi Med Capit...,
-
George M Jr Milne,
Director -
Floyd D Md Loop,
Director -
Advisors Llcisaly Samuel D ...,
-
Michael B Sheffery,
Director -
William C Mulligan,
Director -
Daniel A. Camardo,
CEO